Ò»¡¢¿¹ÌåÒ©Îïͳ¼Æ
´Ó1992ÄêÊ׸ö¿¹ÌåÒ©ÎïOrthocloneÉÏÊÐÒÔÀ´£¬£¬£¬£¬£¬£¬×èÖ¹2016Äê03Ô£¬£¬£¬£¬£¬£¬Î÷Å·ÈÕµÈÖ÷ÒªÊг¡¹²ÉÏÊÐÁË61¸ö¿¹ÌåÒ©Îï¡£¡£¡£¡£¡£20¶àÄê¼ä£¬£¬£¬£¬£¬£¬ÂÄÀúÁË¿¹ÌåÒ©ÎïÑз¢µÄÖî¶àmilestones£º
1992ÄêÉÏÊÐÁËÊ׸öÊóÔ´¿¹ÌåOrthoclone£¬£¬£¬£¬£¬£¬Muromonab£¬£¬£¬£¬£¬£¬ÄªÂÞµ¥¿¹£»£»£»£»£»£»
1993ÄêÉÏÊÐÁËÊ׸öǶºÏµ¥¿¹Reopro£¬£¬£¬£¬£¬£¬Abciximab£¬£¬£¬£¬£¬£¬°ÍÀûÎôµ¥¿¹£»£»£»£»£»£»
1997ÄêÉÏÊÐÁËÊ×СÎÒ˽¼ÒÔ´»¯µ¥¿¹Zenapax£¬£¬£¬£¬£¬£¬Daclizumab£¬£¬£¬£¬£¬£¬´ïÀûÖéµ¥¿¹£»£»£»£»£»£»
1998ÄêÉÏÊÐÁËÈÚºÏÂѰ×Enbrel£¬£¬£¬£¬£¬£¬Etanercept£¬£¬£¬£¬£¬£¬ÒÀÄÇÎ÷ÆÕ£»£»£»£»£»£»
2000ÄêÉÏÊÐÁËÊ׸öADC¿¹ÌåżÁªÒ©ÎïMylotarg£¬£¬£¬£¬£¬£¬GemtuzumabOzogamicin£¬£¬£¬£¬£¬£¬¼ªÍ×µ¥¿¹£»£»£»£»£»£»
2002ÄêÉÏÊÐÁËÊ׸öÈ«ÈËÔ´µ¥¿¹Humira£¬£¬£¬£¬£¬£¬Adalimumab£¬£¬£¬£¬£¬£¬°¢´ïľµ¥¿¹£»£»£»£»£»£»
2006ÄêÉÏÊÐÁË¿¹Ì寬¶ÏFab Lucentis£¬£¬£¬£¬£¬£¬Ranibizumab£¬£¬£¬£¬£¬£¬À×Öéµ¥¿¹£»£»£»£»£»£»
2009ÄêÉÏÊÐÁËÊ׸öË«ÌØÒìÐÔ¿¹ÌåRemovab£¬£¬£¬£¬£¬£¬Catumaxomab£¬£¬£¬£¬£¬£¬¿¨Í×Ë÷µ¥¿¹£»£»£»£»£»£»
2011ÄêÉÏÊÐÁËÊ׸öÖ×ÁöÃâÒßÖÎÁÆ¿¹ÌåYervoy£¬£¬£¬£¬£¬£¬Ipilimumab£¬£¬£¬£¬£¬£¬ÒÁÆ¥µ¥¿¹£»£»£»£»£»£»
2012ÄêÉÏÊÐÁËÊ׸öPD-1¿¹ÌåOpdivo£¬£¬£¬£¬£¬£¬Nivolumab£¬£¬£¬£¬£¬£¬ÄÉÎäµ¥¿¹¡£¡£¡£¡£¡£
±íÒ» 61¸öÉÏÊп¹ÌåÒ©Îïͳ¼Æ
´Ó1992ÄêÊ׸ö¿¹ÌåÒ©ÎïÉÏÊУ¬£¬£¬£¬£¬£¬µ½2015Äê¹²ÉÏÊÐÁË61¸ö¿¹ÌåÒ©Î£¬£¬£¬£¬£¬Æ½¾ùÿÄêÉÏÊÐ2.5¸ö¿¹ÌåÒ©Î£¬£¬£¬£¬£¬ÇÒËÙÂÊÔ½À´Ô½¿ì¡£¡£¡£¡£¡£2014ÄêÉÏÊÐÁË6¸ö¿¹ÌåÒ©Î£¬£¬£¬£¬£¬2015ÄêÉÏÊÐÁË9¸ö¿¹ÌåÒ©Î£¬£¬£¬£¬£¬Ò»Á¬Á½ÄêÍ»ÆÆÀúÊ·¼Í¼¡£¡£¡£¡£¡£
ͼ1 ÀúÄêÉÏÊп¹ÌåÒ©ÎïÊýÄ¿
2015Ä꣬£¬£¬£¬£¬£¬61¸ö¿¹ÌåÒ©ÎïºÏ¼ÆÏúÊÛ¶îµÖ´ï906ÒÚÃÀÔª£¬£¬£¬£¬£¬£¬Óë2014ÄêÏà±ÈÔöÌíÁË8.2%¡£¡£¡£¡£¡£´ÓÏúÊÛÊý¾ÝÀ´¿´£¬£¬£¬£¬£¬£¬Ç°21λµÄ¿¹ÌåÒ©Îï¶¼Áè¼ÝÁË10ÒÚÃÀÔª£¬£¬£¬£¬£¬£¬µÖ´ïÁËÖØ°õÕ¨µ¯µÄ¼¶±ð¡£¡£¡£¡£¡£
±í¶þ ¿¹ÌåÒ©Îï½ü5ÄêÏúÊÛÊý¾Ýͳ¼Æ
Humira¡¢Enbrel¡¢Remicade¡¢Rituxan¡¢Avastin¡¢Herceptin£¬£¬£¬£¬£¬£¬¿¹ÌåÒ©ÎïµÄǰÁùλҩÎïºÏ¼ÆÏúÊÛ¶î¾ÍµÖ´ï520ÒÚÃÀÔª£¬£¬£¬£¬£¬£¬Õ¼µ½Õû¸ö¿¹ÌåÒ©ÎïÊг¡·Ý¶îµÄÒ»°ë»¹¶à¡£¡£¡£¡£¡£Æä´ÎÊÇÑÛ¿ÆÒ©ÎïEyleaºÍLucentis£¬£¬£¬£¬£¬£¬ÓÈÆäÊÇǰÕßµÄÏúÊÛÊý¾ÝÅÊÉýѸËÙ¡£¡£¡£¡£¡£
½ü¼¸ÄêÐÂÉÏÊеĿ¹ÌåÖУ¬£¬£¬£¬£¬£¬³ýÁËEylea£¨ÈÚºÏÂѰף©£¬£¬£¬£¬£¬£¬ÂÞÊϵÄPerjetaºÍADCÒ©ÎïKadcyla¡¢BMSµÄPD-1µ¥¿¹Opdivo¡¢Ä¬É³¶«µÄPD-1µ¥¿¹Keytruda¡¢°²½øµÄPCSK9¿¹ÌåRepatha¡¢Èüŵ·ÆµÄPCSK-9¿¹ÌåPraluent¡¢Åµ»ªµÄIL-17¿¹ÌåCosentyx¡¢ÎäÌïµÄEntyvioµÈ¶¼ÌåÏÖ³öÁËÖØ´óµÄÉÌҵDZÁ¦£¬£¬£¬£¬£¬£¬Ëæ×ŽñÄêµÚÒ»Ìݶӿ¹ÌåÒ©ÎïµÄרÀûÏà¼Ìµ½ÆÚ£¬£¬£¬£¬£¬£¬ÉúÎïÀàËÆÒ©µÄÌæ»»£¬£¬£¬£¬£¬£¬ÕâЩеÄÃ÷ÐÇ¿¹ÌåÒ©Îォ¸Ä±äÕû¸ö¿¹ÌåÊг¡µÄÃûÌᣡ£¡£¡£¡£
ͼ2 ¸÷¿¹ÌåÒ©Îï2015ÄêÏúÊÛ¶î±ÈÕÕ
º£ÄÚ·½Ã棬£¬£¬£¬£¬£¬¿µºëµÄÀÉãåÌåÏÖ¾«²Ê£¬£¬£¬£¬£¬£¬2014ÄêÉÏÊÐ8¸öÔÂʵÏÖÏúÊÛ¶î1ÒÚÔª£¬£¬£¬£¬£¬£¬2015ÄêÏúÊÛ¶îÔ¼3ÒÚÔª¡£¡£¡£¡£¡£ÆÚ´ýØÊºóÊеĸüºÃÌåÏÖ¡£¡£¡£¡£¡£
¶þ¡¢Ò©Æó¿¹ÌåÒ©Îï½á¹¹
±íÈý Ò©Æó¿¹ÌåÒ©ÎïÏúÊÛ¶îͳ¼Æ
ͼ3 ½ü7Ä꿹ÌåÒ©ÎïÊг¡ÈÝÁ¿
´ÓÊýÄ¿ÉÏ¿´£¬£¬£¬£¬£¬£¬ÂÞÊÏÓµÓÐ11¸ö¿¹ÌåÒ©Î£¬£¬£¬£¬£¬Ç¿ÉúÓÐ7¸ö£¬£¬£¬£¬£¬£¬Åµ»ª¡¢BMS¸÷ÓÐ6¸ö£¬£¬£¬£¬£¬£¬GSKÓÐ5¸ö£¬£¬£¬£¬£¬£¬ÀñÀ´¡¢°²½ø¸÷ÓÐ4¸ö£¬£¬£¬£¬£¬£¬ÊÇ¿¹ÌåÒ©Îï×î¶àµÄÆóÒµ¡£¡£¡£¡£¡£
ͼ4 ¸÷Ò©ÆóÉÏÊп¹ÌåÒ©Îï¸öÊý
´ÓÏúÊÛ¶îÉÏ¿´£¬£¬£¬£¬£¬£¬ÂÞÊÏ¿¹ÌåÒ©ÎïÏúÊÛ¶î267ÒÚÃÀÔª£¬£¬£¬£¬£¬£¬°¬²®Î¬¿¿½ü150ÒÚÃÀÔª£¬£¬£¬£¬£¬£¬Ç¿ÉúºÍ°²½ø¾ùÔÚ100ÒÚÃÀÔª×óÓÒ£¬£¬£¬£¬£¬£¬BMS¿¿½ü45ÒÚÃÀÔª¡£¡£¡£¡£¡£5¼Ò¿¹ÌåÒ©Îï¾ÞÍ·ºÏ¼ÆÏúÊÛ¶î¿¿½ü660ÒÚÃÀÔª£¬£¬£¬£¬£¬£¬Õ¼µ½Õû¸ö¿¹ÌåÒ©ÎïÊг¡µÄ73%¡£¡£¡£¡£¡£
ͼ5 ¸÷Ò©Æó2015Ä꿹ÌåÒ©ÎïÊг¡·Ý¶î
Èý¡¢×ܽáÕ¹Íû
¿¹ÌåÀàÒ©ÎïÒѾ³ÉΪÐÂÒ©Ñз¢µÄÖ÷ҪʵÁ¦£¬£¬£¬£¬£¬£¬µÚÒ»´úÖØ°õ¿¹ÌåÒ©ÎïרÀûÏà¼Ìµ½ÆÚ£¬£¬£¬£¬£¬£¬¸÷¹úÕþ¸®Ò½±£¼ç¸ºÖØ£¬£¬£¬£¬£¬£¬¼±Ðè¸ü¸ßÐԼ۱ȵÄÉúÎïÀàËÆÒ©¡£¡£¡£¡£¡£¼¼ÊõÉÏÐÂÐÍ¿¹ÌåÒ©Îï²ã³ö²»Ç£¬£¬£¬£¬£¬Ë«ÌØÒìÐÔ¿¹Ìå¡¢ADCÒ©Îï¡¢Ö×ÁöÃâÒßÁÆ·¨¡¢¿¹Ì寬¶Ï¡¢ÈÚºÏÂѰ׼¼Êõƽ̨£¬£¬£¬£¬£¬£¬Öî¶àм¼ÊõÍÆ¶¯¿¹ÌåÒ©ÎïµÄ¼±ÐèÉú³¤¡£¡£¡£¡£¡£¿£¿£¿¹ÌåÒ©ÎïµÄÓ¦ÓÃÒ²ÒÑ¾ÍØÕ¹µ½°©Ö¢¡¢RAÖ®Íâ¸üÁÉÀ«µÄÖÎÁÆÁìÓò¡£¡£¡£¡£¡£
¶à¹ÉʵÁ¦½»Ö¯£¬£¬£¬£¬£¬£¬Î´À´µÄ¿¹ÌåÒ©ÎïÊг¡ÃûÌûᱬ·¢Éî¿Ìת±ä¡£¡£¡£¡£¡£»£»£»£»£»£Ê±»úÓëÌôÕ½²¢´æ£¬£¬£¬£¬£¬£¬Äã×¼±¸ºÃÁËô£¿£¿£¿